Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for BL-M11D1 (CD33-ADC) Injection for the Treatment of Relapsed or Refractory Myelodysplastic Syndromes The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A